The Cooper Companies, Inc. (NASDAQ:COO) Holdings Decreased by Janus Henderson Group PLC

Janus Henderson Group PLC decreased its holdings in shares of The Cooper Companies, Inc. (NASDAQ:COO) by 1.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,025,356 shares of the medical device company’s stock after selling 53,887 shares during the quarter. Janus Henderson Group PLC’s holdings in Cooper Companies were worth $278,122,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of COO. Barclays PLC grew its holdings in shares of Cooper Companies by 0.7% during the third quarter. Barclays PLC now owns 462,947 shares of the medical device company’s stock valued at $51,082,000 after buying an additional 3,070 shares in the last quarter. Franklin Resources Inc. grew its holdings in shares of Cooper Companies by 194.0% during the third quarter. Franklin Resources Inc. now owns 48,892 shares of the medical device company’s stock valued at $5,265,000 after buying an additional 32,260 shares in the last quarter. Principal Financial Group Inc. grew its stake in Cooper Companies by 6.6% in the third quarter. Principal Financial Group Inc. now owns 238,305 shares of the medical device company’s stock valued at $26,295,000 after purchasing an additional 14,687 shares in the last quarter. JPMorgan Chase & Co. grew its stake in Cooper Companies by 13.2% in the third quarter. JPMorgan Chase & Co. now owns 4,930,022 shares of the medical device company’s stock valued at $543,979,000 after purchasing an additional 573,908 shares in the last quarter. Finally, Graypoint LLC grew its stake in Cooper Companies by 205.9% in the fourth quarter. Graypoint LLC now owns 6,458 shares of the medical device company’s stock valued at $594,000 after purchasing an additional 4,347 shares in the last quarter. Hedge funds and other institutional investors own 24.39% of the company’s stock.

Cooper Companies Price Performance

Shares of NASDAQ:COO opened at $82.27 on Monday. The Cooper Companies, Inc. has a fifty-two week low of $69.81 and a fifty-two week high of $112.38. The business has a 50-day moving average of $80.54 and a two-hundred day moving average of $90.81. The stock has a market capitalization of $16.45 billion, a P/E ratio of 42.19, a P/E/G ratio of 2.25 and a beta of 1.08. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.91 and a quick ratio of 1.12.

Cooper Companies (NASDAQ:COO) last announced its quarterly earnings results on Thursday, March 6th. The medical device company reported $0.92 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.92. Cooper Companies had a return on equity of 9.38% and a net margin of 10.07%. The company had revenue of $964.70 million during the quarter, compared to analysts’ expectations of $981.25 million. On average, equities research analysts predict that The Cooper Companies, Inc. will post 3.98 EPS for the current fiscal year.

Wall Street Analyst Weigh In

COO has been the topic of a number of recent research reports. Stifel Nicolaus lowered their target price on Cooper Companies from $115.00 to $105.00 and set a “buy” rating on the stock in a research note on Friday, March 7th. Robert W. Baird lowered their target price on Cooper Companies from $117.00 to $107.00 and set an “outperform” rating on the stock in a research note on Friday, March 7th. Needham & Company LLC restated a “hold” rating on shares of Cooper Companies in a research note on Friday, March 7th. BNP Paribas upgraded Cooper Companies to a “hold” rating in a research note on Thursday, March 13th. Finally, Citigroup lowered their target price on Cooper Companies from $115.00 to $110.00 and set a “buy” rating on the stock in a research note on Friday, March 7th. Four research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $110.25.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.